Development of Paroxetine Hydrochloride Single Layer Controlled-Release Tablets Based on 3² Factorial Design

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2018 Nov 23

PMID 30463329

Citations 2

Authors

Yao Yang

Zhengwei Huang

Xuan Zhang

Jinyuan Li

Ying Huang

Wanxin Chen

Xin Pan

Chuanbin Wu

Affiliations

Soon will be listed here.

Abstract

Major depressive disorder (MDD) is one of the main contributors to disability and suicide mortality globally. Paroxetine hydrochloride (PHH) is the most potent antidepressant used for MDD treatment. Due to its reduced side effects PAXIL CR is a widely-used controlled-release formulation of PHH. However, the complicated double-layer production of PAXIL CR faces the risk of layer separation. In this study, PHH enteric coating single layer controlled-release tablets (PHH-EC-SLTs) were designed as a simplified substitution of PAXIL CR through a rational formulation screening. The optimized PHH-EC-SLTs showed similar release behaviors in vitro to PAXIL CR and the release profiles corresponded to a zero-order release model (² = 0.9958). Polymer matrix erosion was the main release mechanism, according to the fitting exponents > 1 in the Korsmeyer-Pappas model. Crucial pharmacokinetic parameters including peak-reaching time (), peak concentration () and the area under the blood level-time curve (AUC) of PHH-EC-SLTs and PAXIL CR had no significant difference ( > 0.05) and the relative bioavailability ( = 97.97%) of PHH-EC-SLTs demonstrated their similar pharmacokinetic profiles in vivo. In view of avoiding layer separation risk and simplifying the preparation processing, the self-made PHH-EC-SLTs could be considered as a safe and economic alternative to PAXIL CR.

Citing Articles

Towards a better understanding of thermally treated polycarbophil matrix tablets for controlled release.

Baldassari S, Cirrincione P, Ailuno G, Drava G, Arpicco S, Caviglioli G Int J Pharm X. 2021; 3:100098.

PMID: 34661093 PMC: 8503905. DOI: 10.1016/j.ijpx.2021.100098.

Evaluation of Biodegradable PVA-Based 3D Printed Carriers during Dissolution.

Basa B, Jakab G, Kallai-Szabo N, Borbas B, Fulop V, Balogh E Materials (Basel). 2021; 14(6).

PMID: 33799585 PMC: 7998734. DOI: 10.3390/ma14061350.

References

Wu C, McGinity J . Non-traditional plasticization of polymeric films. Int J Pharm. 1999; 177(1):15-27. DOI: 10.1016/s0378-5173(98)00312-3. View

Conte U, Maggi L . A flexible technology for the linear, pulsatile and delayed release of drugs, allowing for easy accommodation of difficult in vitro targets. J Control Release. 2000; 64(1-3):263-8. DOI: 10.1016/s0168-3659(99)00147-9. View

Siepmann J, Peppas N . Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001; 48(2-3):139-57. DOI: 10.1016/s0169-409x(01)00112-0. View

Kamba M, Seta Y, Kusai A, Nishimura K . Evaluation of the mechanical destructive force in the stomach of dog. Int J Pharm. 2001; 228(1-2):209-17. DOI: 10.1016/s0378-5173(01)00844-4. View

Gohel M, Panchal M . Novel use of similarity factors f2 and Sd for the development of diltiazem HCl modified-release tablets using a 3(2) factorial design. Drug Dev Ind Pharm. 2002; 28(1):77-87. DOI: 10.1081/ddc-120001488. View

Kamba M, Seta Y, Kusai A, Nishimura K . Comparison of the mechanical destructive force in the small intestine of dog and human. Int J Pharm. 2002; 237(1-2):139-49. DOI: 10.1016/s0378-5173(02)00043-1. View

Golden R, Nemeroff C, McSorley P, Pitts C, Dube E . Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry. 2002; 63(7):577-84. DOI: 10.4088/jcp.v63n0707. View

Mann J . The medical management of depression. N Engl J Med. 2005; 353(17):1819-34. DOI: 10.1056/NEJMra050730. View

Varshosaz J, Tavakoli N, Eram S . Use of natural gums and cellulose derivatives in production of sustained release metoprolol tablets. Drug Deliv. 2006; 13(2):113-9. DOI: 10.1080/10717540500313356. View

10.

Dunner D, Lipschitz A, Pitts C, Davies J . Efficacy and tolerability of controlled-release paroxetine in the treatment of severe depression: post hoc analysis of pooled data from a subset of subjects in four double-blind clinical trials. Clin Ther. 2006; 27(12):1901-11. DOI: 10.1016/j.clinthera.2005.12.013. View

11.

Varshosaz J, Tavakoli N, Roozbahani F . Formulation and in vitro characterization of ciprofloxacin floating and bioadhesive extended-release tablets. Drug Deliv. 2006; 13(4):277-85. DOI: 10.1080/10717540500395106. View

12.

Pae C, Patkar A . Paroxetine: current status in psychiatry. Expert Rev Neurother. 2007; 7(2):107-20. DOI: 10.1586/14737175.7.2.107. View

13.

Marks D, Park M, Ham B, Han C, Patkar A, Masand P . Paroxetine: safety and tolerability issues. Expert Opin Drug Saf. 2008; 7(6):783-94. DOI: 10.1517/14740330802423168. View

14.

Gohel M, Parikh R, Nagori S, Jena D . Fabrication of modified release tablet formulation of metoprolol succinate using hydroxypropyl methylcellulose and xanthan gum. AAPS PharmSciTech. 2009; 10(1):62-8. PMC: 2663665. DOI: 10.1208/s12249-008-9174-1. View

15.

Pan J, Lu W, Li C, Wang S, He L . Imperatorin sustained-release tablets: In vitro and pharmacokinetic studies. Arch Pharm Res. 2010; 33(8):1209-16. DOI: 10.1007/s12272-010-0811-3. View

16.

Eisenacher F, Schadlich A, Mader K . Monitoring of internal pH gradients within multi-layer tablets by optical methods and EPR imaging. Int J Pharm. 2010; 417(1-2):204-15. DOI: 10.1016/j.ijpharm.2010.10.010. View

17.

Akhlaq Mughal M, Iqbal Z, Neau S . Guar gum, xanthan gum, and HPMC can define release mechanisms and sustain release of propranolol hydrochloride. AAPS PharmSciTech. 2010; 12(1):77-87. PMC: 3066369. DOI: 10.1208/s12249-010-9570-1. View

18.

Nie S, Wu J, Liu H, Pan W, Liu Y . Influence of admixed citric acid and physiological variables on the vinpocetine release from sodium alginate compressed matrix tablets. Drug Dev Ind Pharm. 2011; 37(8):954-62. DOI: 10.3109/03639045.2010.551774. View

19.

Khatavkar U, Shimpi S, Kumar K, Deo K . Development and comparative evaluation of in vitro, in vivo properties of novel controlled release compositions of paroxetine hydrochloride hemihydrate as against Geomatrix™ platform technology. Drug Dev Ind Pharm. 2012; 39(8):1175-86. DOI: 10.3109/03639045.2012.682222. View

20.

Ferrari A, Somerville A, Baxter A, Norman R, Patten S, Vos T . Global variation in the prevalence and incidence of major depressive disorder: a systematic review of the epidemiological literature. Psychol Med. 2012; 43(3):471-81. DOI: 10.1017/S0033291712001511. View